Sanofi Ventures surpasses $1.4 billion with new capital to accelerate early-stage medical innovation

Sanofi Ventures surpasses $1.4 billion with new capital to accelerate early-stage medical innovation

(IN BRIEF) Sanofi has boosted its venture capital arm, Sanofi Ventures, with a new $625 million multi-year commitment, raising the fund’s assets under management to more than $1.4 billion. Since 2012, Sanofi Ventures has invested over $800 million in more than 70 companies, focusing on biotech and digital health innovations in immunology, rare diseases, neurology, and vaccines. The fund has delivered notable results, including three major exits in 2024 valued at $3.25 billion. Sanofi’s CEO Paul Hudson emphasized that early-stage companies are key to breakthrough science, while Sanofi Ventures Managing Director Jason Hafler underscored the evergreen fund’s strategic importance. With limited access to early-stage biotech financing, the fund is positioned to play a crucial role in advancing transformative therapies, strengthening Sanofi’s innovation pipeline, and reinforcing its position as a leader in healthcare and scientific progress.

(PRESS RELEASE) PARIS, 24-Sep-2025 — /EuropaWire/ — Sanofi has reinforced its commitment to healthcare innovation by allocating an additional $625 million to Sanofi Ventures, bringing the fund’s total assets under management to more than $1.4 billion. This expanded multi-year commitment underscores the company’s long-term strategy of investing in pioneering biotech and digital health enterprises that can transform patient care and generate breakthrough scientific advances.

Sanofi Ventures, the corporate venture capital arm of Sanofi, has been at the forefront of funding early-stage innovation since its inception in 2012. Over the past decade, the fund has invested more than $800 million across over 70 companies worldwide, leading and participating in financing rounds that have propelled advancements in immunology, rare diseases, neurology, and vaccines. With a globally diverse portfolio, the fund actively supports startups from their earliest stages through to IPOs, serving on boards and providing strategic guidance along the way.

Paul Hudson, Chief Executive Officer at Sanofi, emphasized the company’s confidence in the role of early-stage ventures in shaping the future of medicine. “This significant new investment reflects our conviction that some of the most groundbreaking medical innovations begin in small, emerging companies. Sanofi Ventures has a proven history of delivering both strategic wins and successful exits, making it a central driver of scientific progress and growth for our business. By enhancing our investment capabilities, we are strengthening our ability to deliver next-generation therapies and forge valuable partnerships across the healthcare ecosystem.”

Jason P. Hafler, PhD, Managing Director at Sanofi Ventures, highlighted the fund’s achievements and vision for the future. “With this increased capital, we can expand our reach as a strategic investor in scientific and digital health innovation. The strong track record of our fund, including three exits in 2024 with a combined acquisition value of $3.25 billion, underscores the success of our evergreen model and validates our approach to partnering with companies that are leading the way in medical discovery.”

The timing of this expansion is particularly significant given the current challenges in early-stage biotech financing. With funding becoming harder to access, Sanofi Ventures is well-positioned to fill a critical gap by offering both financial support and strategic expertise to startups pursuing transformative therapies. This initiative not only reinforces Sanofi’s research pipeline but also strengthens its role as a global catalyst for advancing science and healthcare innovation.

Sanofi continues to build on its reputation as an R&D-driven, AI-enabled biopharma leader, leveraging its deep expertise in immunology and other core therapeutic areas to address urgent healthcare needs. With this renewed commitment to venture investment, the company is setting the stage for long-term growth and innovation that has the potential to improve millions of lives worldwide.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward looking statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi.

SOURCE: Sanofi